ErycibellineCAS# 107633-95-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 107633-95-4 | SDF | Download SDF |
| PubChem ID | 129917 | Appearance | Powder |
| Formula | C7H13NO2 | M.Wt | 143.18 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 8-azabicyclo[3.2.1]octane-4,6-diol | ||
| SMILES | C1CC(C2C(CC1N2)O)O | ||
| Standard InChIKey | GXCZZQGJZNJSBW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C7H13NO2/c9-5-2-1-4-3-6(10)7(5)8-4/h4-10H,1-3H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1.Erycibelline has antiobesity activity, it may be a useful therapeutic agent for body weight control by downregulating adipogenesis and lipogenesis. |
| Targets | LDL | PPAR |
Erycibelline Dilution Calculator
Erycibelline Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.9842 mL | 34.9211 mL | 69.8422 mL | 139.6843 mL | 174.6054 mL |
| 5 mM | 1.3968 mL | 6.9842 mL | 13.9684 mL | 27.9369 mL | 34.9211 mL |
| 10 mM | 0.6984 mL | 3.4921 mL | 6.9842 mL | 13.9684 mL | 17.4605 mL |
| 50 mM | 0.1397 mL | 0.6984 mL | 1.3968 mL | 2.7937 mL | 3.4921 mL |
| 100 mM | 0.0698 mL | 0.3492 mL | 0.6984 mL | 1.3968 mL | 1.7461 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Dehydroformouregine
Catalog No.:BCN4054
CAS No.:107633-69-2
- PF 998425
Catalog No.:BCC7811
CAS No.:1076225-27-8
- 4-Hydroxycoumarin
Catalog No.:BCN2561
CAS No.:1076-38-6
- 4-Demethyl-3,9-dihydroeucomin
Catalog No.:BCN5876
CAS No.:107585-77-3
- 3'-Hydroxy-3,9-dihydroeucomin
Catalog No.:BCN5875
CAS No.:107585-75-1
- Anwulignan
Catalog No.:BCN5362
CAS No.:107534-93-0
- Omadacycline tosylate
Catalog No.:BCC5136
CAS No.:1075240-43-5
- Glucagon-like peptide 1 (7-36) amide (human, rat)
Catalog No.:BCC7258
CAS No.:107444-51-9
- Bisabola-2,10-diene-1,9-dione
Catalog No.:BCN7269
CAS No.:107439-25-8
- Ginkgolide J
Catalog No.:BCN5939
CAS No.:107438-79-9
- CD 1530
Catalog No.:BCC7406
CAS No.:107430-66-0
- Garcinone D
Catalog No.:BCN2526
CAS No.:107390-08-9
- Merucathinone
Catalog No.:BCN1783
CAS No.:107638-80-2
- Bulleyaconitine A
Catalog No.:BCN1210
CAS No.:107668-79-1
- Merucathine
Catalog No.:BCN1782
CAS No.:107673-74-5
- beta-Lipoic acid
Catalog No.:BCC9198
CAS No.:6992-30-9
- MDL 11,939
Catalog No.:BCC6822
CAS No.:107703-78-6
- Epleremone
Catalog No.:BCC3776
CAS No.:107724-20-9
- Methyl 7beta,15-dihydroxydehydroabietate
Catalog No.:BCN7270
CAS No.:107752-10-3
- Zafirlukast
Catalog No.:BCC4881
CAS No.:107753-78-6
- A 61603 hydrobromide
Catalog No.:BCC6912
CAS No.:107756-30-9
- Coccinic acid
Catalog No.:BCN5877
CAS No.:107783-45-9
- 3,4-Dihydroxybenzenepropanoic acid
Catalog No.:BCN8500
CAS No.:1078-61-1
- PF 04418948
Catalog No.:BCC6299
CAS No.:1078166-57-0
Antiobesity Effects of Unripe Rubus coreanus Miquel and Its Constituents: An In Vitro and In Vivo Characterization of the Underlying Mechanism.[Pubmed:26904142]
Evid Based Complement Alternat Med. 2016;2016:4357656.
Background. The objective of the present study was to perform a bioguided fractionation of unripe Rubus coreanus Miquel (uRC) and evaluate the lipid accumulation system involvement in its antiobesity activity as well as study the uRC mechanism of action. Results. After the fractionation, the BuOH fraction of uRC (uRCB) was the most active fraction, suppressing the differentiation of 3T3-L1 adipocytes in a dose-dependent manner. Moreover, after an oral administration for 8 weeks in HFD-induced obese mice, uRCB (10 and 50 mg/kg/day) produced a significant decrease in body weight, food efficiency ratio, adipose tissue weight and LDL-cholesterol, serum glucose, TC, and TG levels. Similarly, uRCB significantly suppressed the elevated mRNA levels of PPARgamma in the adipose tissue in vivo. Next, we investigated the antiobesity effects of ellagic acid, Erycibelline, 5-hydroxy-2-pyridinemethanol, m-hydroxyphenylglycine, and 4-hydroxycoumarin isolated from uRCB. Without affecting cell viability, five bioactive compounds decreased the lipid accumulation in the 3T3-L1 cells and the mRNA expression levels of key adipogenic genes such as PPARgamma, C/EBPalpha, SREBP-1c, ACC, and FAS. Conclusion. These results suggest that uRC and its five bioactive compounds may be a useful therapeutic agent for body weight control by downregulating adipogenesis and lipogenesis.
A concise stereoselective synthesis of (-)-erycibelline.[Pubmed:21946951]
Org Biomol Chem. 2011 Oct 26;9(22):7713-9.
(-)-Erycibelline, the dihydroxynortropane alkaloid isolated from Erycibe elliptilimba Merr. et Chun., was synthesized using a cyclic nitrone as advanced intermediate, wherein the key step was the SmI(2)-induced intramolecular reductive coupling of cyclic nitrone with aldehyde which resulted in good yield and stereoselectivity.
